Apogee Therapeutics, INC Schedule 13G passive stakes

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 0.9% of Apogee Therapeutics, Inc. common stock as of June 30, 2026.

T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, reporting beneficial ownership of 772,969 shares, representing 1.3% of the outstanding common stock of Apogee Therapeutics Inc.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 4.0% of Apogee Therapeutics Inc.'s common stock as of June 30, 2026.

T. Rowe Price Investment Management, Inc. has reported a beneficial ownership of 16.8% in Apogee Therapeutics Inc. as of March 31, 2026.

The Vanguard Group filed an amended Schedule 13G, indicating it no longer holds beneficial ownership in Apogee Therapeutics Inc. following an internal realignment.

T. Rowe Price Investment Management, Inc. has disclosed an 11.3% beneficial ownership stake in Apogee Therapeutics Inc. common stock.

RTW Investments, LP and Roderick Wong, M.D. have reported a 4.9% beneficial ownership stake in Apogee Therapeutics, Inc. common stock.

Wellington Management Group LLP and its affiliates disclosed a beneficial ownership of 8.66% in Apogee Therapeutics, Inc. common stock as of December 31, 2025.

The Vanguard Group has reported a 5.21% beneficial ownership stake in Apogee Therapeutics Inc. common stock as of December 31, 2025.

Driehaus Capital Management LLC has reported a 4.68% beneficial ownership stake in Apogee Therapeutics, Inc., holding 2,158,502 shares of common stock.

FMR LLC and Abigail P. Johnson have disclosed a 15.0% beneficial ownership stake in Apogee Therapeutics Inc., totaling 6,907,100 common shares.

Wellington Management Group and its affiliates have reported a 10.6% beneficial ownership stake in Apogee Therapeutics, Inc. common stock.

Wellington Management Group and its affiliates have disclosed a passive beneficial ownership of 8.26% in Apogee Therapeutics, Inc. common stock.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 5.5% beneficial ownership stake in Apogee Therapeutics Inc., totaling 2,518,725 common shares.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting beneficial ownership of 11.9% of Apogee Therapeutics, Inc.'s common stock as of March 31, 2025.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a 6% beneficial ownership stake in Apogee Therapeutics, Inc. as of December 31, 2024.